Invited lectures

Keynote EMAS Lectures

• Postmenopausal health and Risks in Europe - Lessons from the EPIC study 
• A whole-life perspective on ageing: insights from the 1946 British birth cohort
• The Ageing World - Challenges Ahead
• The WHO risk calculator for fracture risk in the prevention of Osteoperosis
• Making sense of sex hormones and dementia
• Medicines, Individuals and Populations
• Making Sense of Risk

Parallel Sessions

Obesity and Health in Post-Menopausal Women

• Obesity-a silent killer?
• Impact of obesity on common menopausal problems
• How to put forward a national prevention program against obesity and cancers
• Management of obesity
  

Perimenopause

• Contraception after 45
• Premenstrual Syndrome
• Aetiology of POF
• Managing Premature ovarian failure

Sexual Health in postmenopausal women

• STI’s in older people and epidemiology
• Vaginal immunity
• HIV
• Maintaining Sexual health

Individualising Therapy for Climacteric Symptoms

• Assessing impact of treatment on QoL
• Vasomotor symptoms
• Climacteric Depression
• Joint Aches & Pains

Breast Management

• Primary prevention and risk factors
• Does screening reduce mortality in Europe
• Making an individual risk assessment
• From Biology to Clinical Trials
  

HRT & Breast Cancer Risk

• Where are we with HRT?
• Managing Oestrogen deficiency after Breast Cancer
• Decreasing incidence in Breast Cancer
• What is the impact of HRT on screening

Brain function in postmenopausal women

• Hormones and the brain
• Demylenation disorders and hormonal influences
• Minimal Cognitive impairment and Menopause: Individualising risk
• The effects of hormones on cognition and dementia

Osteoporosis and fracture

• HT as a front line option for fracture prevention
• Advances in non-hormonal drug therapy for fracture prevention
• BMD in prediction of other conditions
• Vertebral body quality, effect of HRT and fracture in the osteoperosis

Cardiovascular disease

• Can we avoid thrombosis risk with HT
• Is there really a window of opportunity?
• Stroke and the menopause
• Individual cardiovascular risk assessment and risk reduction strategies
  

Sexual function

• Sexuality in older couples
• Androgens and postmenopausal sexuality
• Sexual dysfunction in Female ageing
• Sexual dysfunction in male ageing
  

Professional development in menopause practice - Europe

• UK special interest training in menopause
• Training for menopause practice in Scandinavia
• Professional development in menopause, Turkey
• Professional development in menopause, Romania

New Developments for tomorrow

• SERMs and related regimins
• Progestogens/antiprogestins
• Non-hormonal drugs in menopause
• Pharmacogenetics

Urogenital aging

• The prevalence of female urinary incontinence in the community
• Managing uro-genital atrophy
• Maintaining standards in surgery for female urinary incontinence
• Preserving vaginal function after prolapse surgery

Complementary approaches in the management of the menopause

• Therapeutic approaches
• Dietary approaches
• Acupuncture
• Exercise & Lifestyle

The ageing male

• How to diagnose testosterone deficiency in the ageing male
• Treatment options for testosterone deficiency
• Safety
• ISSAM recommendations for the diagnosis and management of LOH

The menopausal uterus and ovary

• Understanding uterine bleeding
• Ovarian cancer risk, screening and HRT
• Benign gynaecology after the menopause
• Practical Assessment of the endometrium

Menopause Conference Debates

• Progestin or Progesterone - ther is no real difference

•   Long-term prevention of osteoporosis starting at the menopause is preferable to later targeting of women at high fracture risk

• HRT has a place in reducing cardiovascular risk